Skip to main content

Table 3 Treatment-Related AEs

From: Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study

Adverse Event

RC48

 

RC48 + ICIs

 

All Grade

≥ Grade3

All Grade

≥ Grade3

Hematologic

    

 Decreased white blood count

11(55.0)

2(10.0)

 

14(56.0)

3(12.0)

 

 Decreased neutrophil count

11(55.0)

2(10.0)

 

13(52.0)

3(12.0)

 

 Decreased platelet

4(20.0)

1(5.0)

 

4(16.0)

0

 

 Anemia

3(15.0)

1(5.0)

 

5(20.0)

1(4.0)

 

 Increased ALT

9(45.0)

0

 

9(32.0)

1(4.0)

 

 Increased AST

9(45.0)

0

 

8(32.0)

1(4.0)

 

 Hyperbilirubinemia

2(10.0)

0

 

3(12.0)

0

 

 TSH elevation

0

0

 

4(16.0)

0

 

Non-hematologic

      

 Fatigue

12(60.0)

0

 

14(56.0)

0

 

 Nausea or Vomiting

5(25.0)

0

 

4(16.0)

0

 

 Diarrhea

3(15.0)

0

 

3(12.0)

1(4.0)

 

 Pyrexia

3(15.0)

0

 

4(16.0)

0

 

 Muscle pain/joint pain

4(20.0)

1(5.0)

 

5(20.0)

0

 

 Hypoaesthesia

11(55.0)

2(10.0)

 

14(56.0)

2(8.0)

 

 Loss of appetite

8(40.0)

0

 

10(40.0)

0

 

 Alopecia

13(65.0)

0

 

15(60.0)

0

 

 Weight loss

6(30.0)

0

 

8(32.0)

0

 

 Rash

2(10.0)

0

 

4(16.0)

0

 

 Pruritus

5(25.0)

0

 

5(20.0)

0

 

 Pneumonitis

0

0

 

2(8.0)

1(4.0)

 

 Hypothyroidism

0

0

 

4(16.0)

0

 

 Abdominal pain

3(15.0)

0

 

2(8.0)

0

 
  1. AE, adverse event